Shijiazhuang Huaxin Pharmaceutical Co., Ltd.

Levoamlodipine Besylate Tablets provided by Shijiazhuang Huaxin Pharmaceutical Co., Ltd. were used as the test preparation, and amlodipine Besylate Tablets produced by Pfizer Pharmaceuticals Co., Ltd. were used as the reference preparation to evaluate the relative bioavailability and bioequivalence in humans.

Main purpose: Through a fasting/postprandial test study, the in vivo pharmacokinetic characteristics of a single oral dose of pioglitazone metformin tablets (specifications: 15mg/500mg/tablet) developed and provided by Shijiazhuang Huaxin Pharmaceutical Co., Ltd. and pioglitazone metformin tablets (specifications: 15mg/500mg/tablet) produced by Takeda Teba Pharmaceutical Co., Ltd. were investigated in healthy Chinese subjects under fasting/postprandial conditions, and the bioequivalence of the two preparations was evaluated. Secondary purpose: Evaluate the safety of a single oral dose of pioglitazone metformin tablets (specifications: 15mg/500mg/tablet) and the reference preparation in healthy Chinese subjects.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of sacubitril-valsartan sodium tablets (specification: 200 mg (sacubitril 97 mg/valsartan 103 mg)) produced by Shijiazhuang Huaxin Pharmaceutical Co., Ltd. and sacubitril-valsartan sodium tablets (specification: 200 mg (sacubitril 97 mg/valsartan 103 mg)) produced by Novartis Pharma Schweiz AG in healthy Chinese subjects after a single oral dose under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of a single oral dose of sacubitril-valsartan sodium tablets (specification: 200 mg (sacubitril 97 mg/valsartan 103 mg)) and reference preparations in healthy Chinese subjects.